<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35790708</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.</ArticleTitle><Pagination><StartPage>1061</StartPage><EndPage>1084</EndPage><MedlinePgn>1061-1084</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-022-01260-5</ELocationID><Abstract><AbstractText>Nuclear clearance and cytoplasmic mislocalization of the essential RNA binding protein, TDP-43, is a pathologic hallmark of amyotrophic lateral sclerosis, frontotemporal dementia, and related neurodegenerative disorders collectively termed "TDP-43 proteinopathies." TDP-43 mislocalization causes neurodegeneration through both loss and gain of function mechanisms. Loss of TDP-43 nuclear RNA processing function destabilizes the transcriptome by multiple mechanisms including disruption of pre-mRNA splicing, the failure of repression of cryptic exons, and retrotransposon activation. The accumulation of cytoplasmic TDP-43, which is prone to aberrant liquid-liquid phase separation and aggregation, traps TDP-43 in the cytoplasm and disrupts a host of downstream processes including the trafficking of RNA granules, local translation within axons, and mitochondrial function. In this review, we will discuss the TDP-43 therapy development pipeline, beginning with therapies in current and upcoming clinical trials, which are primarily focused on accelerating the clearance of TDP-43 aggregates. Then, we will look ahead to emerging strategies from preclinical studies, first from high-throughput genetic and pharmacologic screens, and finally from mechanistic studies focused on the upstream cause(s) of TDP-43 disruption in ALS/FTD. These include modulation of stress granule dynamics, TDP-43 nucleocytoplasmic shuttling, RNA metabolism, and correction of aberrant splicing events.</AbstractText><CopyrightInformation>&#xa9; 2022. The American Society for Experimental NeuroTherapeutics, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hayes</LastName><ForeName>Lindsey R</ForeName><Initials>LR</Initials><Identifier Source="ORCID">0000-0003-4818-6054</Identifier><AffiliationInfo><Affiliation>Johns Hopkins School of Medicine, Dept. of Neurology, Baltimore, MD, USA. lhayes@jhmi.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalab</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Whiting School of Engineering, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R03 NS127011</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS123538</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS104273</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018626">Retroelements</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012322">RNA Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018626" MajorTopicYN="N">Retroelements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012322" MajorTopicYN="N">RNA Precursors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="Y">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Autophagy</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">RNA</Keyword><Keyword MajorTopicYN="N">Stress granules</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>5</Day><Hour>23</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35790708</ArticleId><ArticleId IdType="pmc">PMC9587158</ArticleId><ArticleId IdType="doi">10.1007/s13311-022-01260-5</ArticleId><ArticleId IdType="pii">10.1007/s13311-022-01260-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front Mol Neurosci. 2019;12:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Fran&#xe7;ois-Moutal L, Perez-Miller S, Scott DD, Miranda VG, Mollasalehi N, Khanna M. Structural insights Into TDP-43 and effects of post-translational modifications. Front Mol Neurosci. 2019;12:1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6934062</ArticleId><ArticleId IdType="pubmed">31920533</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Bioph Res Co. 2006;351:602&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Velde CV, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40:572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Deerlin VMV, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 2008;7:409&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3546119</ArticleId><ArticleId IdType="pubmed">18396105</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, Levitch D, et al. TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol. 2008;63:535&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747362</ArticleId><ArticleId IdType="pubmed">18288693</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Bonvicini C, Alberici A, Buratti E, Agosti C, Archetti S, et al. Mutation within TARDBP leads to Frontotemporal Dementia without motor neuron disease. Hum Mutat. 2009;30:E974&#x2013;E983.</Citation><ArticleIdList><ArticleId IdType="pubmed">19655382</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Murrell JR, Horvath S, Haraszti L, Majtenyi K, Molnar MJ, et al. TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. Movement Disord. 2009;24:1842&#x2013;1847.</Citation><ArticleIdList><ArticleId IdType="pubmed">19609911</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Functional significance of TDP-43 mutations in disease. Adv Genet. 2015;91:1&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">26410029</ArticleId></ArticleIdList></Reference><Reference><Citation>Broeck LV, Callaerts P, Dermaut B. TDP-43-mediated neurodegeneration: towards a loss-of-function hypothesis? Trends Mol Med. 2014;20:66&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">24355761</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Ann Neurol. 2007;61:435&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Youmans KL, Wolozin B. TDP-43: a new player on the AD field? Exp Neurol. 2012;237:90&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3910368</ArticleId><ArticleId IdType="pubmed">22691390</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Mackenzie IRA, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K, et al. Phosphorylated TDP-43 in Alzheimer&#x2019;s disease and dementia with Lewy bodies. Acta Neuropathol. 2009;117:125&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">19139911</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Gavett BE, Stern RA, Nowinski CJ, Cantu RC, Kowall NW, et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2010;69:918&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951281</ArticleId><ArticleId IdType="pubmed">20720505</ArticleId></ArticleIdList></Reference><Reference><Citation>Thammisetty SS, Pedragosa J, Weng YC, Calon F, Planas A, Kriz J. Age-related deregulation of TDP-43 after stroke enhances NF-&#x3ba;B-mediated inflammation and neuronal damage. J Neuroinflammation. 2018;15:312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6230239</ArticleId><ArticleId IdType="pubmed">30413172</ArticleId></ArticleIdList></Reference><Reference><Citation>Masaki K, Sonobe Y, Ghadge G, Pytel P, L&#xe9;pine P, Pernin F, et al. RNA-binding protein altered expression and mislocalization in MS. Neurol Neuroimmunol Neuroinflammation.&#xa0;2020;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7176246</ArticleId><ArticleId IdType="pubmed">32217641</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer EMJ, Orie VK, Williams T, Baker MR, Oliveira HMD, Polvikoski T, et al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurology Neurosurg Psychiatry. 2021;92:86&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7803890</ArticleId><ArticleId IdType="pubmed">33177049</ArticleId></ArticleIdList></Reference><Reference><Citation>Weihl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurology Neurosurg Psychiatry. 2008;79:1186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586594</ArticleId><ArticleId IdType="pubmed">18796596</ArticleId></ArticleIdList></Reference><Reference><Citation>Salajegheh M, Pinkus JL, Taylor JP, Amato AA, Nazareno R, Baloh RH, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve. 2009;40:19&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700211</ArticleId><ArticleId IdType="pubmed">19533646</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;sters B, van Hoeve BJA, Schelhaas HJ, ter Laak H, van Engelen BGM, Lammens M. TDP-43 accumulation is common in myopathies with rimmed vacuoles. Acta Neuropathol. 2009;117:209&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">19066918</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP. Multisystem proteinopathy Intersecting genetics in muscle, bone, and brain degeneration. Neurology. 2015;85:658&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">26208960</ArticleId></ArticleIdList></Reference><Reference><Citation>Apontes, P. Chapter 9 - New opportunities for treatment of neurodegenerative disease through the modulation of TDP-43, in TDP-43 and Neurodegeneration. (eds. V. Kumar &amp; M.K. Jaiswal) p183-250 (Academic Press, 2022).</Citation></Reference><Reference><Citation>Buratti E. Targeting TDP-43 proteinopathy with drugs and drug-like small molecules. Brit J Pharmacol. 2021;178:1298&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">32469420</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo V, Tosat-Bitrian C, Nozal V, Nagaraj S, Martin-Requero A, Martinez A. TDP-43: a key therapeutic target beyond amyotrophic lateral sclerosis. Acs Chem Neurosci. 2019;10:1183&#x2013;1196.</Citation><ArticleIdList><ArticleId IdType="pubmed">30785719</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, Zago P, D&#x2019;Ambrogio A, Xu YF, Petrucelli L, Buratti E, et al. Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci. 2008;121:3778&#x2013;3785.</Citation><ArticleIdList><ArticleId IdType="pubmed">18957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011;14:452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14:459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349:650&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Q, Yalamanchili HK, Park J, Maio AD, Lu HC, Wan YW, et al. Extensive cryptic splicing upon loss of RBM17 and TDP43 in neurodegeneration models. Hum Mol Genet. 2016;ddw337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5968355</ArticleId><ArticleId IdType="pubmed">28007900</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, L&#xf3;pez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22:180&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Rot G, Wang Z, Huppertz I, Modic M, Len&#x10d;e T, Hallegger M, et al. High-resolution RNA maps suggest common principles of splicing and polyadenylation regulation by TDP-43. Cell Rep. 2017;19:1056&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5437728</ArticleId><ArticleId IdType="pubmed">28467899</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam OH, Rozhkov NV, Shaw R, Kim D, Hubbard I, Fennessey S, et al. Postmortem cortex samples identify distinct molecular subtypes of ALS: retrotransposon activation, oxidative stress, and activated glia. Cell Rep. 2019;29:1164&#x2013;1177.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6866666</ArticleId><ArticleId IdType="pubmed">31665631</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano G, Klima R, Feiguin F. TDP-43 prevents retrotransposon activation in the Drosophila motor system through regulation of Dicer-2 activity. Bmc Biol. 2020;18:82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334854</ArticleId><ArticleId IdType="pubmed">32620127</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y, Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc National Acad Sci. 2012;109:3347&#x2013;3352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3295278</ArticleId><ArticleId IdType="pubmed">22323604</ArticleId></ArticleIdList></Reference><Reference><Citation>Saldi TK, Ash PE, Wilson G, Gonzales P, Garrido-Lecca A, Roberts CM, et al. TDP-1, the Caenorhabditis elegans ortholog of TDP-43, limits the accumulation of double-stranded RNA. Embo J. 2014;33:2947&#x2013;2966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4282642</ArticleId><ArticleId IdType="pubmed">25391662</ArticleId></ArticleIdList></Reference><Reference><Citation>Birsa N, Bentham MP, Fratta P. Cytoplasmic functions of TDP-43 and FUS and their role in ALS. Semin Cell Dev Biol. 2019;99:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">31132467</ArticleId></ArticleIdList></Reference><Reference><Citation>Afroz T, Hock EM, Ernst P, Foglieni C, Jambeau M, Gilhespy LAB, et al. Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nat Commun. 2017;8:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5491494</ArticleId><ArticleId IdType="pubmed">28663553</ArticleId></ArticleIdList></Reference><Reference><Citation>Portz B, Lee BL, Shorter J. FUS and TDP-43 phases in health and disease. Trends Biochem Sci. 2021;46:550&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8195841</ArticleId><ArticleId IdType="pubmed">33446423</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella AE, Dignon GL, Zerze GH, Schmidt HB, D&#x2019;Ordine AM, Kim YC, et al. TDP-43 &#x3b1;-helical structure tunes liquid&#x2013;liquid phase separation and function. Proc National Acad Sci. 2020;117:5883&#x2013;5894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7084079</ArticleId><ArticleId IdType="pubmed">32132204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallegger M, Chakrabarti AM, Lee FCY, Lee BL, Amalietti AG, Odeh HM, et al. TDP-43 condensation properties specify its RNA-binding and regulatory repertoire. Cell. 2021;184:4680&#x2013;4696.e22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8445024</ArticleId><ArticleId IdType="pubmed">34380047</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella AE, Zerze GH, Mittal J, Fawzi NL. ALS mutations disrupt phase separation mediated by &#x3b1;-helical structure in the TDP-43 low-complexity c-terminal domain. Structure. 2016;24:1537&#x2013;1549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014597</ArticleId><ArticleId IdType="pubmed">27545621</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt HB, Barreau A, Rohatgi R. Phase separation-deficient TDP43 remains functional in splicing. Nat Commun. 2019;10:4890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6814767</ArticleId><ArticleId IdType="pubmed">31653829</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. TDP-43 post-translational modifications in health and disease. Expert Opin Ther Tar. 2018;22:279&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">29431050</ArticleId></ArticleIdList></Reference><Reference><Citation>Tziortzouda P, Bosch LVD, Hirth F. Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation. Nat Rev Neurosci. 2021;22:197&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">33654312</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura AL, Zupunski V, Troakes C, Kathe C, Fratta P, Howell M, et al. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain. 2010;133:1763&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472655</ArticleId></ArticleIdList></Reference><Reference><Citation>Archbold HC, Jackson KL, Arora A, Weskamp K, Tank EMH, Li X, et al. TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. Sci Rep. 2018;8:4606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5854632</ArticleId><ArticleId IdType="pubmed">29545601</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinarbasi ES, Ca&#x11f;atay T, Fung HYJ, Li YC, Chook YM, Thomas PJ. Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization. Sci Rep. 2018;8:7083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935693</ArticleId><ArticleId IdType="pubmed">29728608</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle H, Funk C, Abou-Ajram C, Hutten S, Funk EBE, Kehlenbach RH, et al. Nuclear egress of TDP-43 and FUS occurs independently of Exportin-1/CRM1. Sci Rep. 2018;8:7084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935713</ArticleId><ArticleId IdType="pubmed">29728564</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan L, Zaepfel BL, Aksenova V, Dasso M, Rothstein JD, Kalab P, et al. Nuclear RNA binding regulates TDP-43 nuclear localization and passive nuclear export. Cell Rep. 2022;In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9345261</ArticleId><ArticleId IdType="pubmed">35858577</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson Y, Kelley T, Mackenzie IRA, Pickering-Brown S, Plessis DD, Neary D, et al. Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol. 2007;113:521&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">17219193</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodansky A, Kim JMH, Tempest L, Velagapudi A, Libby R, Ravits J. TDP-43 and ubiquitinated cytoplasmic aggregates in sporadic ALS are low frequency and widely distributed in the lower motor neuron columns independent of disease spread. Amyotroph Lateral Sc. 2010;11:321&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4981144</ArticleId><ArticleId IdType="pubmed">20225928</ArticleId></ArticleIdList></Reference><Reference><Citation>Berning BA, Walker AK. The pathobiology of TDP-43 C-terminal fragments in ALS and FTLD. Front Neurosci-switz. 2019;13:335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6470282</ArticleId><ArticleId IdType="pubmed">31031584</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatsavayai SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JNS, Trujillo A, et al. Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain. 2016;139:3202&#x2013;3216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790143</ArticleId><ArticleId IdType="pubmed">27797809</ArticleId></ArticleIdList></Reference><Reference><Citation>Nana AL, Sidhu M, Gaus SE, Hwang JHL, Li L, Park Y, et al. Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology. Acta Neuropathol. 2019;137:27&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6339592</ArticleId><ArticleId IdType="pubmed">30511086</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong YH, Ling JP, Lin SZ, Donde AN, Braunstein KE, Majounie E, et al. Tdp-43 cryptic exons are highly variable between cell types. Mol Neurodegener. 2017;12:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5289002</ArticleId><ArticleId IdType="pubmed">28153034</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, et al. TDP-43 represses cryptic exon inclusion in the FTD&#x2013;ALS gene UNC13A. Nature. 2022;603:124&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL, Wilkins OG, Keuss MJ, Hill SE, Zanovello M, Lee WC, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603:131&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, Ling SC, Huelga SC, Lagier-Tourenne C, Polymenidou M, Ditsworth D, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci. 2013;110:E736&#x2013;E745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, Kim E, Duffy A, Adalbert R, Phillips BU, Peters OM, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21:552&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu EY, Russ J, Cali CP, Phan JM, Amlie-Wolf A, Lee EB. Loss of Nuclear TDP-43 Is Associated with Decondensation of LINE Retrotransposons. Cell Rep. 2019;27:1409&#x2013;1421.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6508629</ArticleId><ArticleId IdType="pubmed">31042469</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Xu YF, Cook C, Gendron TF, Roettges P, Link CD, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci. 2009;106:7607&#x2013;7612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YT, Kuo PH, Chiang CH, Liang JR, Chen YR, Wang S, et al. The truncated C-terminal RNA recognition motif of TDP-43 protein plays a key role in forming proteinaceous aggregates*. J Biol Chem. 2013;288:9049&#x2013;9057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3610977</ArticleId><ArticleId IdType="pubmed">23372158</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen AKH, Lin RYY, Hsieh EZJ, Tu PH, Chen RPY, Liao TY, et al. Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. J Am Chem Soc. 2010;132:1186&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">20055380</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Z, Deng J, Zhao W, Yang J. Amyloid-like aggregation and fibril core determination of TDP-43 C-terminal domain. Biochem Bioph Res Co. 2020;532:655&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">32907712</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, Spiller KJ, Ge G, Zheng A, Xu Y, Zhou M, et al. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol. 2015;130:643&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127391</ArticleId><ArticleId IdType="pubmed">26197969</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Chen Y, Zhou X, Kar A, Ray P, Chen X, et al. An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nat Struct Mol Biol. 2011;18:822&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3357956</ArticleId><ArticleId IdType="pubmed">21666678</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Kametani F, Arai T, Akiyama H, Hasegawa M. Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet. 2009;18:3353&#x2013;3364.</Citation><ArticleIdList><ArticleId IdType="pubmed">19515851</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity*. J Biol Chem. 2009;284:20329&#x2013;20339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A, Gumina V, Lenzi P, Bossolasco P, Fulceri F, Volpe C, et al. Chronic stress induces formation of stress granules and pathological TDP-43 aggregates in human ALS fibroblasts and iPSC-motoneurons. Neurobiol Dis. 2020;145:105051.</Citation><ArticleIdList><ArticleId IdType="pubmed">32827688</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C, Zennaro E, Fallini C, Weber M, Sommacal A, Buratti E, et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem. 2009;111:1051&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">19765185</ArticleId></ArticleIdList></Reference><Reference><Citation>Babinchak WM, Haider R, Dumm BK, Sarkar P, Surewicz K, Choi JK, et al. The role of liquid&#x2013;liquid phase separation in aggregation of the TDP-43 low-complexity domain. J Biol Chem. 2019;294:6306&#x2013;6317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6484124</ArticleId><ArticleId IdType="pubmed">30814253</ArticleId></ArticleIdList></Reference><Reference><Citation>Hans F, Glasebach H, Kahle PJ. Multiple distinct pathways lead to hyperubiquitylated insoluble TDP-43 protein independent of its translocation into stress granules. J Biol Chem. 2020;295:673&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6970928</ArticleId><ArticleId IdType="pubmed">31780563</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, Gleixner AM, Mauna JC, Gomes E, DeChellis-Marks MR, Needham PG, et al. RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43. Neuron. 2019;102:321&#x2013;338.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Otte CG, Fortuna TR, Mann JR, Gleixner AM, Ramesh N, Pyles NJ, et al. Optogenetic TDP-43 nucleation induces persistent insoluble species and progressive motor dysfunction in vivo. Neurobiol Dis. 2020;146:105078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9040199</ArticleId><ArticleId IdType="pubmed">32927062</ArticleId></ArticleIdList></Reference><Reference><Citation>Asakawa K, Handa H, Kawakami K. Optogenetic modulation of TDP-43 oligomerization accelerates ALS-related pathologies in the spinal motor neurons. Nat Commun. 2020;11:1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7035286</ArticleId><ArticleId IdType="pubmed">32081878</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, Lu S, Yu H, Chen C, Melamed Z, Guo L, et al. Cytoplasmic TDP-43 de-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron. 2019;102:339&#x2013;357.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta S, Xu Y, Restrepo CR, Kwong LK, Zhang B, Brown HJ, et al. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat Commun. 2018;9:4220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6181940</ArticleId><ArticleId IdType="pubmed">30310141</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Cohen TJ. Aggregation of the nucleic acid&#x2013;binding protein TDP-43 occurs via distinct routes that are coordinated with stress granule formation. J Biol Chem. 2019;294:3696&#x2013;3706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416430</ArticleId><ArticleId IdType="pubmed">30630951</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbet GA, Wheeler JR, Parker R, Weskamp K. TDP43 ribonucleoprotein granules: physiologic function to pathologic aggregates. RNA Biol. 2021;1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8677035</ArticleId><ArticleId IdType="pubmed">34412568</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou CC, Zhang Y, Umoh ME, Vaughan SW, Lorenzini I, Liu F, et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat Neurosci. 2018;21:228&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer RC, Chami AA, de Assis DR, Vourc&#x2019;h P, Andres CR, Corcia P, et al. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight? Brain. 2019;142:1176&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Amlie-Wolf A, Ryvkin P, Tong R, Dragomir I, Suh E, Xu Y, et al. Transcriptomic changes due to cytoplasmic TDP-43 expression reveal dysregulation of histone transcripts and nuclear chromatin. PLoS ONE. 2015;10:e0141836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4624943</ArticleId><ArticleId IdType="pubmed">26510133</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman T, Ionescu A, Ibraheem A, Priesmann D, Gradus-Pery T, Farberov L, et al. Axonal TDP-43 condensates drive neuromuscular junction disruption through inhibition of local synthesis of nuclear encoded mitochondrial proteins. Nat Commun. 2021;12:6914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8617040</ArticleId><ArticleId IdType="pubmed">34824257</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Wang L, Lu J, Siedlak SL, Fujioka H, Liang J, et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat Med. 2016;22:869&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4974139</ArticleId><ArticleId IdType="pubmed">27348499</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CH, Davidson S, Harapas CR, Hilton JB, Mlodzianoski MJ, Laohamonthonkul P, et al. TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell. 2020;183:636&#x2013;649.e18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucini CB, Braun RJ. Mitochondrion-Dependent Cell Death in TDP-43 Proteinopathies. Biomed. 2021;9:376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8066287</ArticleId><ArticleId IdType="pubmed">33918437</ArticleId></ArticleIdList></Reference><Reference><Citation>Miguel L, Fr&#xe9;bourg T, Campion D, Lecourtois M. Both cytoplasmic and nuclear accumulations of the protein are neurotoxic in Drosophila models of TDP-43 proteinopathies. Neurobiol Dis. 2011;41:398&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">20951205</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella R, Capitini C, Fani G, Dobson CM, Cecchi C, Chiti F. Quantification of the relative contributions of loss-of-function and gain-of-function mechanisms in TAR DNA-binding protein 43 (TDP-43) proteinopathies*. J Biol Chem. 2016;291:19437&#x2013;19448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016682</ArticleId><ArticleId IdType="pubmed">27445339</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihevc SP, Baralle M, Buratti E, Rogelj B. TDP-43 aggregation mirrors TDP-43 knockdown, affecting the expression levels of a common set of proteins. Sci Rep-UK. 2016;6:33996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5036055</ArticleId><ArticleId IdType="pubmed">27665936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, Conti LD, Avenda&#xf1;o-V&#xe1;zquez SE, Dhir A, Romano M, D&#x2019;Ambrogio A, et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 2011;30:277&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025456</ArticleId><ArticleId IdType="pubmed">21131904</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama A, Sugai A, Kato T, Ishihara T, Shiga A, Toyoshima Y, et al. Increased cytoplasmic TARDBP mRNA in affected spinal motor neurons in ALS caused by abnormal autoregulation of TDP-43. Nucleic Acids Res. 2016;44:5820&#x2013;5836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4937342</ArticleId><ArticleId IdType="pubmed">27257061</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Fan H, Ying Z, Li B, Wang H, Wang G. Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system. Neurosci Lett. 2010;469:112&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">19944744</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella R, Fani G, Capitini C, Rusmini P, Poletti A, Cecchi C, et al. Quantitative assessment of the degradation of aggregated TDP-43 mediated by the ubiquitin proteasome system and macroautophagy. Faseb J. 2017;31:5609&#x2013;5624.</Citation><ArticleIdList><ArticleId IdType="pubmed">28842427</ArticleId></ArticleIdList></Reference><Reference><Citation>Orme&#xf1;o F, Hormazabal J, Moreno J, Riquelme F, Rios J, Criollo A, et al. Chaperone mediated autophagy degrades TDP-43 protein and is affected by TDP-43 aggregation. Front Mol Neurosci. 2020;13:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7040037</ArticleId><ArticleId IdType="pubmed">32132902</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, Vance C, Nishimura AL, Lee YB, Chen HJ, Urwin H, et al. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. J Cell Sci. 2014;127:1263&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3953816</ArticleId><ArticleId IdType="pubmed">24424030</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Coyne AN, Pei F, Vaughan S, Chaung M, Zarnescu DC, et al. Endocytosis regulates TDP-43 toxicity and turnover. Nat Commun. 2017;8:2092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5727062</ArticleId><ArticleId IdType="pubmed">29233983</ArticleId></ArticleIdList></Reference><Reference><Citation>Bose JK, Huang CC, Shen CKJ. Regulation of autophagy by neuropathological protein TDP-43*. J Biol Chem. 2011;286:44441&#x2013;44448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3247982</ArticleId><ArticleId IdType="pubmed">22052911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Zhang X, Song L, Le W. Autophagy dysregulation in amyotrophic lateral sclerosis. Brain Pathol. 2012;22:110&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029048</ArticleId><ArticleId IdType="pubmed">22150926</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Jeon YM, Cha SJ, Kim S, Kwon Y, Jo M, et al. PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARDBP/TDP-43 proteinopathies. Autophagy. 2019;16:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7469499</ArticleId><ArticleId IdType="pubmed">31690171</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibiger C, Deisel J, Aufschnaiter A, Ambros S, Tereshchenko M, Verheijen BM, et al. TDP-43 controls lysosomal pathways thereby determining its own clearance and cytotoxicity. Hum Mol Genet. 2018;27:1593&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pubmed">29474575</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin P, Bai D, Zhu L, Deng F, Guo X, Li B, et al. Cytoplasmic TDP-43 impairs the activity of the ubiquitin-proteasome system. Exp Neurol. 2021;345:113833.</Citation><ArticleIdList><ArticleId IdType="pubmed">34363810</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzies FM, Fleming A, Caricasole A, Bento CF, Andrews SP, Ashkenazi A, et al. Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities. Neuron. 2017;93:1015&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pubmed">28279350</ArticleId></ArticleIdList></Reference><Reference><Citation>Bov&#xe9; J, Mart&#xed;nez-Vicente M, Vila M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci. 2011;12:437&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">21772323</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang IF, Guo BS, Liu YC, Wu CC, Yang CH, Tsai KJ, et al. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc National Acad Sci. 2012;109:15024&#x2013;15029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3443184</ArticleId><ArticleId IdType="pubmed">22932872</ArticleId></ArticleIdList></Reference><Reference><Citation>Mislang A, Mollard R, Rico GT, Fairlie WD, Lee EF, Harris TJ, et al. A preliminary assessment of oral monepantel&#x2019;s tolerability and pharmacokinetics in individuals with treatment-refractory solid tumors. Cancer Chemoth Pharm. 2020;86:589&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">32960289</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack R, Stephens J, Barkhaus PE, Bereman M, Caress JB, Crayle J, et al. ALSUntangled 59: Tamoxifen. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">33474997</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen PC, Hsieh YC, Huang CC, Hu CJ. Tamoxifen for amyotrophic lateral sclerosis: A randomized double-blind clinical trial. Medicine. 2020;99:e20423.</Citation><ArticleIdList><ArticleId IdType="pubmed">32481440</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu S, Macklin EA, Jackson KE, Simpson E, Mahoney K, Yu H, et al. Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;21:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31608711</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K, Izumi Y, Watanabe A, Tsukita K, Woltjen K, Yamamoto T, et al. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med. 2017;9:eaaf3962.</Citation><ArticleIdList><ArticleId IdType="pubmed">28539470</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenqiang C, Lonskaya I, Hebron ML, Ibrahim Z, Olszewski RT, Neale JH, et al. Parkin-mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice. Hum Mol Genet. 2014;23:4960&#x2013;4969.</Citation><ArticleIdList><ArticleId IdType="pubmed">24847002</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Liu FT, Wang YX, Guan RY, Chen C, Li DK, et al. Autophagic modulation by trehalose reduces accumulation of TDP-43 in a cell model of amyotrophic lateral sclerosis via TFEB activation. Neurotox Res. 2018;34:109&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">29383655</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P, Cortese K, Crippa V, Cristofani R, Cicardi ME, Ferrari V, et al. Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration. Autophagy. 2018;15:631&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6526812</ArticleId><ArticleId IdType="pubmed">30335591</ArticleId></ArticleIdList></Reference><Reference><Citation>Holler CJ, Taylor G, McEachin ZT, Deng Q, Watkins WJ, Hudson K, et al. Trehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: a novel therapeutic lead to treat frontotemporal dementia. Mol Neurodegener. 2016;11:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4919863</ArticleId><ArticleId IdType="pubmed">27341800</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo K, Nassif M, Valenzuela V, Rojas F, Matus S, Mercado G, et al. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy. 2013;9:1308&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pubmed">23851366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Yoon YS, Lee SJ. Mechanism of neuroprotection by trehalose: controversy surrounding autophagy induction. Cell Death Dis. 2018;9:712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6003909</ArticleId><ArticleId IdType="pubmed">29907758</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee GC, Lin CH, Tao YC, Yang JM, Hsu KC, Huang YJ, et al. The potential of lactulose and melibiose, two novel trehalase-indigestible and autophagy-inducing disaccharides, for polyQ-mediated neurodegenerative disease treatment. Neurotoxicology. 2015;48:120&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">25800379</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Wang H, Ying Z, Gao Q. Ibudilast enhances the clearance of SOD1 and TDP-43 aggregates through TFEB-mediated autophagy and lysosomal biogenesis: The new molecular mechanism of ibudilast and its implication for neuroprotective therapy. Biochem Bioph Res Co. 2020;526:231&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">32204915</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu S, Hightower BG, Chan J, Z&#xfc;rcher NR, Kivis&#xe4;kk P, Tseng CEJ, et al. Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial. Neuroimage Clin. 2021;30:102672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8102622</ArticleId><ArticleId IdType="pubmed">34016561</ArticleId></ArticleIdList></Reference><Reference><Citation>Aulas A, Stabile S, Velde CV. Endogenous TDP-43, but not FUS, contributes to stress granule assembly via G3BP. Mol Neurodegener. 2012;7:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3502460</ArticleId><ArticleId IdType="pubmed">23092511</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald KK, Aulas A, Destroismaisons L, Pickles S, Beleac E, Camu W, et al. TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum Mol Genet. 2011;20:1400&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pubmed">21257637</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalfallah Y, Kuta R, Grasmuck C, Prat A, Durham HD, Velde CV. TDP-43 regulation of stress granule dynamics in neurodegenerative disease-relevant cell types. Sci Rep. 2018;8:7551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5953947</ArticleId><ArticleId IdType="pubmed">29765078</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderweyde T, Vanderwyde T, Citro A, et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS ONE. 2010;5:e13250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952586</ArticleId><ArticleId IdType="pubmed">20948999</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain S, Wheeler JR, Walters RW, Agrawal A, Barsic A, Parker R. ATPase-modulated stress granules contain a diverse proteome and substructure. Cell. 2016;164:487&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4733397</ArticleId><ArticleId IdType="pubmed">26777405</ArticleId></ArticleIdList></Reference><Reference><Citation>Protter DSW, Parker R. Principles and properties of stress granules. Trends Cell Biol. 2016;26:668&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4993645</ArticleId><ArticleId IdType="pubmed">27289443</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Ivanov P. Stress granules and neurodegeneration. Nat Rev Neurosci. 2019;20:649&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6986315</ArticleId><ArticleId IdType="pubmed">31582840</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproviero W, Shatunov A, Stahl D, Shoai M, van Rheenen W, Jones AR, et al. ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiol Aging. 2017;51:178.e1&#x2013;178.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5302215</ArticleId><ArticleId IdType="pubmed">28017481</ArticleId></ArticleIdList></Reference><Reference><Citation>Eck RJ, Kraemer BC, Liachko NF. Regulation of TDP-43 phosphorylation in aging and disease. Geroscience. 2021;43:1605&#x2013;1614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8492835</ArticleId><ArticleId IdType="pubmed">34032984</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Gonz&#xe1;lez L, Gonzalo-Consuegra C, G&#xf3;mez-Almer&#xed;a M, Porras G, de Lago E, Mart&#xed;n-Requero &#xc1;, et al. Tideglusib, a non-ATP competitive inhibitor of GSK-3&#x3b2; as a drug candidate for the treatment of amyotrophic lateral sclerosis. Int J Mol Sci. 2021;22:8975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8396476</ArticleId><ArticleId IdType="pubmed">34445680</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YM, Gupta SK, Kim KJ, Powers BE, Cerqueira A, Wainger BJ, et al. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell. 2013;12:713&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707511</ArticleId><ArticleId IdType="pubmed">23602540</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolosa E, Litvan I, H&#xf6;glinger GU, Burn D, Lees A, Andr&#xe9;s MV, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014;29:470&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">24532007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovestone S, Boada M, Dubois B, H&#xfc;ll M, Rinne JO, Huppertz HJ, et al. A phase II trial of tideglusib in Alzheimer&#x2019;s disease. J Alzheimer&#x2019;s Dis. 2015;45:75&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">25537011</ArticleId></ArticleIdList></Reference><Reference><Citation>Crippa V, D&#x2019;Agostino VG, Cristofani R, Rusmini P, Cicardi ME, Messi E, et al. Transcriptional induction of the heat shock protein B8 mediates the clearance of misfolded proteins responsible for motor neuron diseases. Sci Rep-UK. 2016;6:22827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4785366</ArticleId><ArticleId IdType="pubmed">26961006</ArticleId></ArticleIdList></Reference><Reference><Citation>Crippa V, Cicardi ME, Ramesh N, Seguin SJ, Ganassi M, Bigi I, et al. The chaperone HSPB8 reduces the accumulation of truncated TDP-43 species in cells and protects against TDP-43-mediated toxicity. Hum Mol Genet. 2016;25:3908&#x2013;3924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5291228</ArticleId><ArticleId IdType="pubmed">27466192</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganassi M, Mateju D, Bigi I, Mediani L, Poser I, Lee HO, et al. A surveillance function of the HSPB8-BAG3-HSP70 chaperone complex ensures stress granule integrity and dynamism. Mol Cell. 2016;63:796&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">27570075</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Crippa V, Cereda C, Bonetto V, Zucchi E, Gessani A, et al. Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS) BMJ Open. 2019;9:e028486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6549675</ArticleId><ArticleId IdType="pubmed">31152038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Chetrit E, Bergmann S, Sood R. Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis. Rheumatology. 2006;45:274&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">16188942</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD. Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Met. 2015;11:1781&#x2013;1794.</Citation><ArticleIdList><ArticleId IdType="pubmed">26239119</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, Phaneuf D, Dupr&#xe9; N, Petri S, Strong M, Kriz J, et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor &#x3ba;B&#x2013;mediated pathogenic pathways. J Exp Med. 2011;208:2429&#x2013;2447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh JH, Lee TJ, Park JW, Kwon TK. Withaferin A inhibits iNOS expression and nitric oxide production by Akt inactivation and down-regulating LPS-induced activity of NF-&#x3ba;B in RAW 264.7 cells. Eur J Pharmacol. 2008;599:11&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">18838070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Phaneuf D, Julien JP. Withaferin-A treatment alleviates TAR DNA-binding protein-43 pathology and improves cognitive function in a mouse model of FTLD. Neurotherapeutics. 2021;18:286&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8116414</ArticleId><ArticleId IdType="pubmed">33078279</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta K, Patel P, Rahimian R, Phaneuf D, Julien JP. Withania somnifera reverses transactive response DNA binding protein 43 proteinopathy in a mouse model of amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Neurotherapeutics. 2017;14:447&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5398980</ArticleId><ArticleId IdType="pubmed">27928708</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C, protease activated receptor 1, and neuroprotection. Blood. 2018;132:159&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6043978</ArticleId><ArticleId IdType="pubmed">29866816</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, Ilieva H, Hallagan L, Bell R, Singh I, Paquette N, et al. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest. 2009;119:3437&#x2013;3449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2769191</ArticleId><ArticleId IdType="pubmed">19841542</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sengillo JD, Sagare AP, Zhao Z, Ma Q, Zuniga E, et al. Blood&#x2013;spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci. 2014;111:E1035&#x2013;E1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964055</ArticleId><ArticleId IdType="pubmed">24591593</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen YT, Yang HR, Lo HC, Hsieh YC, Tsai SC, Hong CW, et al. Enhancing autophagy with activated protein C and rapamycin protects against sepsis-induced acute lung injury. Surgery. 2013;153:689&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">23434181</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Hung ST, Rocha G, Lin S, Linares G, Staats KA, et al. Identification and therapeutic rescue of autophagosome and glutamate receptor defects in C9ORF72 and sporadic ALS neurons. JCI Insight. 2019;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6693831</ArticleId><ArticleId IdType="pubmed">31310593</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Raphael AR, LaDow ES, McGurk L, Weber R, Trojanowski JQ, et al. Therapeutic modulation of eIF2&#x3b1;-phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet. 2014;46:152&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3934366</ArticleId><ArticleId IdType="pubmed">24336168</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon SL, Sonenberg N, Parker R. Neuronal Regulation of eIF2&#x3b1; function in health and neurological disorders. Trends Mol Med. 2018;24:575&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">29716790</ArticleId></ArticleIdList></Reference><Reference><Citation>Armakola M, Higgins MJ, Figley MD, Barmada SJ, Scarborough EA, Diaz Z, et al. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat Genet. 2012;44:1302&#x2013;1309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3510335</ArticleId><ArticleId IdType="pubmed">23104007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Rahman MH, Park D, Jo M, Kim HJ, Suk K. identification of genetic modifiers of TDP-43: inflammatory activation of astrocytes for neuroinflammation. Cells. 2021;10:676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8003223</ArticleId><ArticleId IdType="pubmed">33803845</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko NF, McMillan PJ, Guthrie CR, Bird TD, Leverenz JB, Kraemer BC. CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Ann Neurol. 2013;74:39&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3775949</ArticleId><ArticleId IdType="pubmed">23424178</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko NF, McMillan PJ, Strovas TJ, Loomis E, Greenup L, Murrell JR, et al. The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43. Plos Genet. 2014;10:e1004803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4256087</ArticleId><ArticleId IdType="pubmed">25473830</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor LM, McMillan PJ, Liachko NF, Strovas TJ, Ghetti B, Bird TD, et al. Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration. Mol Neurodegener. 2018;13:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5802059</ArticleId><ArticleId IdType="pubmed">29409526</ArticleId></ArticleIdList></Reference><Reference><Citation>Nozal V, Mart&#xed;nez-Gonz&#xe1;lez L, Gomez-Almeria M, Gonzalo-Consuegra C, Santana P, Chaikuad A, et al. TDP-43 modulation by tau-tubulin kinase 1 inhibitors: a new avenue for future amyotrophic lateral sclerosis therapy. J Med Chem. 2022;65:1585&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pubmed">34978799</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaca G, Martinez-Gonzalez L, Fernandez A, Rojas-Prats E, Porras G, Cuevas EP, et al. Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDP-43-related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) J Neurochem. 2021;156:379&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">32628315</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko NF, Saxton AD, McMillan PJ, Strovas TJ, Keene CD, Bird TD, et al. Genome wide analysis reveals heparan sulfate epimerase modulates TDP-43 proteinopathy. Plos Genet. 2019;15:e1008526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6934317</ArticleId><ArticleId IdType="pubmed">31834878</ArticleId></ArticleIdList></Reference><Reference><Citation>Meneghetti MCZ, Hughes AJ, Rudd TR, Nader HB, Powell AK, Yates EA, et al. Heparan sulfate and heparin interactions with proteins. J Roy Soc Interface. 2015;12:20150589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4614469</ArticleId><ArticleId IdType="pubmed">26289657</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheis N, Jiang M, Selleck SB. Putting the brakes on autophagy: The role of heparan sulfate modified proteins in the balance of anabolic and catabolic pathways and intracellular quality control. Matrix Biol. 2021;100:173&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">33548399</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan L, Xie Q, Tibbetts RS. Opposing roles of p38 and JNK in a Drosophila model of TDP-43 proteinopathy reveal oxidative stress and innate immunity as pathogenic components of neurodegeneration. Hum Mol Genet. 2015;24:757&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4291250</ArticleId><ArticleId IdType="pubmed">25281658</ArticleId></ArticleIdList></Reference><Reference><Citation>Pichon CEL, Meilandt WJ, Dominguez S, Solanoy H, Lin H, Ngu H, et al. Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. Sci Transl Med. 2017;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28814543</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian R, Gachechiladze MA, Ludwig CH, Laurie MT, Hong JY, Nathaniel D, et al. CRISPR interference-based platform for multimodal genetic screens in human iPSC-derived neurons. Neuron. 2019;104:239&#x2013;255.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813890</ArticleId><ArticleId IdType="pubmed">31422865</ArticleId></ArticleIdList></Reference><Reference><Citation>Siu M, Ghosh AS, Lewcock JW. Dual Leucine Zipper Kinase Inhibitors for the Treatment of Neurodegeneration. J Med Chem. 2018;61:8078&#x2013;8087.</Citation><ArticleIdList><ArticleId IdType="pubmed">29863360</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz JS, Rothstein JD, Cudkowicz ME, Genge A, Oskarsson B, Hains AB, et al. A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS. Ann Clin Transl Neur. 2022;9:50&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8791798</ArticleId><ArticleId IdType="pubmed">35014217</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Neukomm LJ, Brown RH, Freeman MR. Age-dependent TDP-43-mediated motor neuron degeneration requires GSK3, hat-trick, and xmas-2. Curr Biol. 2015;25:2130&#x2013;2136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4546534</ArticleId><ArticleId IdType="pubmed">26234214</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C, Song W, Bi X, Zhao J, Huang Z, Li Z, et al. Recent advances in the ARID family: focusing on roles in human cancer. Oncotargets Ther. 2014;7:315&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3933769</ArticleId><ArticleId IdType="pubmed">24570593</ArticleId></ArticleIdList></Reference><Reference><Citation>Woldegebriel R, Kvist J, Andersson N, &#xd5;unap K, Reinson K, Wojcik MH, et al. Distinct effects on mRNA export factor GANP underlie neurological disease phenotypes and alter gene expression depending on intron content. Hum Mol Genet. 2020;29:1426&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7297229</ArticleId><ArticleId IdType="pubmed">32202298</ArticleId></ArticleIdList></Reference><Reference><Citation>Berson A, Sartoris A, Nativio R, Deerlin VV, Toledo JB, Porta S, et al. TDP-43 Promotes Neurodegeneration by Impairing Chromatin Remodeling. Curr Biol. 2017;27:3579&#x2013;3590.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5720388</ArticleId><ArticleId IdType="pubmed">29153328</ArticleId></ArticleIdList></Reference><Reference><Citation>Kankel MW, Sen A, Lu L, Theodorou M, Dimlich DN, McCampbell A, et al. Amyotrophic lateral sclerosis modifiers in Drosophila reveal the phospholipase D pathway as a potential therapeutic target. Genetics. 2020 doi: 10.1534/genetics.119.302985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.119.302985</ArticleId><ArticleId IdType="pmc">PMC7337071</ArticleId><ArticleId IdType="pubmed">32345615</ArticleId></ArticleIdList></Reference><Reference><Citation>Conforti FL, Spataro R, Sproviero W, Mazzei R, Cavalcanti F, Condino F, et al. Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis. Neurology. 2012;79:2315&#x2013;2320.</Citation><ArticleIdList><ArticleId IdType="pubmed">23197749</ArticleId></ArticleIdList></Reference><Reference><Citation>Nousiainen HO, Kestil&#xe4; M, Pakkasj&#xe4;rvi N, Honkala H, Kuure S, Tallila J, et al. Mutations in mRNA export mediator GLE1 result in a fetal motoneuron disease. Nat Genet. 2008;40:155&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684619</ArticleId><ArticleId IdType="pubmed">18204449</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneb HM, Folkmann AW, Belzil VV, Jao LE, Leblond CS, Girard SL, et al. Deleterious mutations in the essential mRNA metabolism factor, hGle1, in amyotrophic lateral sclerosis. Hum Mol Genet. 2015;24:1363&#x2013;1373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4321443</ArticleId><ArticleId IdType="pubmed">25343993</ArticleId></ArticleIdList></Reference><Reference><Citation>Azpurua J, El-Karim EG, Tranquille M, Dubnau J. A behavioral screen for mediators of age-dependent TDP-43 neurodegeneration identifies SF2/SRSF1 among a group of potent suppressors in both neurons and glia. PLoS Genet. 2021;17:e1009882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8584670</ArticleId><ArticleId IdType="pubmed">34723963</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen BL, Taatjes DJ. The Mediator complex: a central integrator of transcription. Nat Rev Mol Cell Bio. 2015;16:155&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4963239</ArticleId><ArticleId IdType="pubmed">25693131</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, Berson A, Kennerdell JR, Sartoris A, Unger T, Porta S, et al. Aberrant activation of non-coding RNA targets of transcriptional elongation complexes contributes to TDP-43 toxicity. Nat Commun. 2018;9:4406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6199344</ArticleId><ArticleId IdType="pubmed">30353006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura M, Imamoto N. Biological significance of the importin-&#x3b2; family-dependent nucleocytoplasmic transport pathways. Traffic (Copenhagen, Denmark) 2014;15:727&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">24766099</ArticleId></ArticleIdList></Reference><Reference><Citation>Harel A, Forbes DJ. Importin beta: conducting a much larger cellular symphony. Mol Cell. 2004;16:319&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">15525506</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Zhan L, Hanson KA, Tibbetts RS. High-content RNAi screening identifies the Type 1 inositol triphosphate receptor as a modifier of TDP-43 localization and neurotoxicity. Hum Mol Genet. 2012;21:4845&#x2013;4856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529575</ArticleId><ArticleId IdType="pubmed">22872699</ArticleId></ArticleIdList></Reference><Reference><Citation>Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol. 2010;9:885&#x2013;894.</Citation><ArticleIdList><ArticleId IdType="pubmed">20723845</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Chung CG, Park SS, Lee D, Kim KM, Jeong Y, et al. Cytosolic calcium regulates cytoplasmic accumulation of TDP-43 through Calpain-A and Importin &#x3b1;3. Elife. 2020;9:e60132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7748415</ArticleId><ArticleId IdType="pubmed">33305734</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhardt MF, Martinez FJ, Wright S, Ramos C, Volfson D, Mason M, et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol Cell Neurosci. 2013;56:355&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4772428</ArticleId><ArticleId IdType="pubmed">23891805</ArticleId></ArticleIdList></Reference><Reference><Citation>Noel P, Hoff DDV, Saluja AK, Velagapudi M, Borazanci E, Han H. Triptolide and its derivatives as cancer therapies. Trends Pharmacol Sci. 2019;40:327&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">30975442</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd JD, Lee-Armandt JP, Feiler MS, Zaarur N, Liu M, Kraemer B, et al. A High-Content Screen Identifies Novel Compounds That Inhibit Stress-Induced TDP-43 Cellular Aggregation and Associated Cytotoxicity. J Biomol Screen. 2013;19:44&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3913261</ArticleId><ArticleId IdType="pubmed">24019256</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang MY, Markmiller S, Vu AQ, Javaherian A, Dowdle WE, Jolivet P, et al. Small-molecule modulation of TDP-43 recruitment to stress granules prevents persistent TDP-43 accumulation in ALS/FTD. Neuron. 2019;103:802&#x2013;819.e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6728177</ArticleId><ArticleId IdType="pubmed">31272829</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A, Malinovska L, Saha S, Wang J, Alberti S, Krishnan Y, et al. ATP as a biological hydrotrope. Science. 2017;356:753&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522535</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallardo G, Barowski J, Ravits J, Siddique T, Lingrel JB, Robertson J, et al. An &#x3b1;2-Na/K ATPase/&#x3b1;-adducin complex in astrocytes triggers non&#x2013;cell autonomous neurodegeneration. Nat Neurosci. 2014;17:1710&#x2013;1719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4703324</ArticleId><ArticleId IdType="pubmed">25344630</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccioni F, Roman BR, Fischbeck KH, Taylor JP. A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor. Hum Mol Genet. 2004;13:437&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">14709594</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer RM, Mayer B, Kuncl RW, Check DP, Cahoon EK, Rivera DR, et al. Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of medicare prescription drugs. Amyotroph Lateral Scler Frontotemporal Degener. 2019;21:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9930913</ArticleId><ArticleId IdType="pubmed">31684770</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapuscinski J, Darzynkiewicz Z. Relationship between the pharmacological activity of antitumor drugs Ametantrone and mitoxantrone (Novatrone) and their ability to condense nucleic acids. Proc Natl Acad Sci. 1986;83:6302&#x2013;6306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC386491</ArticleId><ArticleId IdType="pubmed">3462696</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain A, Vale RD. RNA phase transitions in repeat expansion disorders. Nature. 2017;546:243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5555642</ArticleId><ArticleId IdType="pubmed">28562589</ArticleId></ArticleIdList></Reference><Reference><Citation>Korth C, May BCH, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc National Acad Sci. 2001;98:9836&#x2013;9841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC55539</ArticleId><ArticleId IdType="pubmed">11504948</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zanden SY, Qiao X, Neefjes J. New insights into the activities and toxicities of the old anticancer drug doxorubicin. FEBS J. 2021;288:6095&#x2013;6111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8597086</ArticleId><ArticleId IdType="pubmed">33022843</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Q, Zhou L, Xu S, Li X, Zou Y, Chen J. High doses of daunorubicin during induction therapy of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis of prospective clinical trials. PLoS ONE. 2015;10:e0125612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439155</ArticleId><ArticleId IdType="pubmed">25993000</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocco E, Marrosu MG. The current role of mitoxantrone in the treatment of multiple sclerosis. Expert Rev Neurother. 2014;14:607&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">24834466</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato Y, Sakamoto K. Niclosamide affects intracellular TDP-43 distribution in motor neurons, activates mitophagy, and attenuates morphological changes under stress. J Biosci Bioeng. 2021;132:640&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">34429248</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Mook RA, Premont RT, Wang J. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018;41:89&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5628105</ArticleId><ArticleId IdType="pubmed">28389414</ArticleId></ArticleIdList></Reference><Reference><Citation>Milani M, Mammarella E, Rossi S, Miele C, Lattante S, Sabatelli M, et al. Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis. J Neuroinflamm. 2021;18:132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8196441</ArticleId><ArticleId IdType="pubmed">34118929</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F, Nonaka T, Suzuki T, Arai T, Dohmae N, Akiyama H, et al. Identification of casein kinase-1 phosphorylation sites on TDP-43. Biochem Bioph Res Co. 2009;382:405&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">19285963</ArticleId></ArticleIdList></Reference><Reference><Citation>Salado IG, Redondo M, Bello ML, Perez C, Liachko NF, Kraemer BC, et al. Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. J Med Chem. 2014;57:2755&#x2013;2772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969104</ArticleId><ArticleId IdType="pubmed">24592867</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez DI, Gil C, Martinez A. Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Med Res Rev. 2011;31:924&#x2013;954.</Citation><ArticleIdList><ArticleId IdType="pubmed">20577972</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas-Prats E, Martinez-Gonzalez L, Gonzalo-Consuegra C, Liachko NF, Perez C, Ram&#xed;rez D, et al. Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis. Eur J Med Chem. 2021;210:112968.</Citation><ArticleIdList><ArticleId IdType="pubmed">33139113</ArticleId></ArticleIdList></Reference><Reference><Citation>Fran&#xe7;ois-Moutal L, Felemban R, Scott DD, Sayegh MR, Miranda VG, Perez-Miller S, et al. Small molecule targeting TDP-43&#x2019;s RNA recognition motifs reduces locomotor defects in a Drosophila model of amyotrophic lateral sclerosis (ALS) ACS Chem Biol. 2019;14:2006&#x2013;2013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6911355</ArticleId><ArticleId IdType="pubmed">31241884</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollasalehi N, Francois-Moutal L, Scott DD, Tello JA, Williams H, Mahoney B, et al. An allosteric modulator of RNA binding targeting the N-terminal domain of TDP-43 yields neuroprotective properties. ACS Chem Biol. 2020;15:2854&#x2013;2859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8548910</ArticleId><ArticleId IdType="pubmed">33044808</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue YC, Ng CS, Xiang P, Liu H, Zhang K, Mohamud Y, et al. Dysregulation of RNA-binding proteins in amyotrophic lateral sclerosis. Front Mol Neurosci. 2020;13:78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273501</ArticleId><ArticleId IdType="pubmed">32547363</ArticleId></ArticleIdList></Reference><Reference><Citation>Darling AL, Shorter J. Combating deleterious phase transitions in neurodegenerative disease. Biochimica Et Biophysica Acta Bba - Mol Cell Res. 2021;1868:118984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7965345</ArticleId><ArticleId IdType="pubmed">33549703</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, Donnelly CJ. RNA modulates physiological and neuropathological protein phase transitions. Neuron. 2021;109:2663&#x2013;2681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8434763</ArticleId><ArticleId IdType="pubmed">34297914</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes N, Nero L, Lyons SM, Ivanov P, Mittelmeier TM, Bolger TA, et al. Stress granule assembly can facilitate but is not required for TDP-43 cytoplasmic aggregation. Biomol. 2020;10:1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7650667</ArticleId><ArticleId IdType="pubmed">32992901</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribbeck K, G&#xf6;rlich D. The permeability barrier of nuclear pore complexes appears to operate via hydrophobic exclusion. EMBO J. 2002;21:2664&#x2013;2671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC126029</ArticleId><ArticleId IdType="pubmed">12032079</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulga N, Goldfarb DS. Binding dynamics of structural nucleoporins govern nuclear pore complex permeability and may mediate channel gating. Mol Cell Biol. 2003;23:534&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151542</ArticleId><ArticleId IdType="pubmed">12509452</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberti S, Gladfelter A, Mittag T. Considerations and challenges in studying liquid-liquid phase separation and biomolecular condensates. Cell. 2019;176:419&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6445271</ArticleId><ArticleId IdType="pubmed">30682370</ArticleId></ArticleIdList></Reference><Reference><Citation>Babinchak WM, Dumm BK, Venus S, Boyko S, Putnam AA, Jankowsky E, et al. Small molecules as potent biphasic modulators of protein liquid-liquid phase separation. Nat Commun. 2020;11:5574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7643064</ArticleId><ArticleId IdType="pubmed">33149109</ArticleId></ArticleIdList></Reference><Reference><Citation>French RL, Grese ZR, Aligireddy H, Dhavale DD, Reeb AN, Kedia N, et al. Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation. J Biol Chem. 2019;294:6696&#x2013;6709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6497947</ArticleId><ArticleId IdType="pubmed">30824544</ArticleId></ArticleIdList></Reference><Reference><Citation>Grese ZR, Bastos AC, Mamede LD, French RL, Miller TM, Ayala YM. Specific RNA interactions promote TDP-43 multivalent phase separation and maintain liquid properties. Embo Rep. 2021;22:e53632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8647020</ArticleId><ArticleId IdType="pubmed">34787357</ArticleId></ArticleIdList></Reference><Reference><Citation>Maharana S, Wang J, Papadopoulos DK, Richter D, Pozniakovsky A, Poser I, et al. RNA buffers the phase separation behavior of prion-like RNA binding proteins. Science. 2018;360:918&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091854</ArticleId><ArticleId IdType="pubmed">29650702</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Wang L, Ren X, Dunn JR, Peters A, Miyagi M, et al. Translational regulation in the brain by TDP-43 phase separation. J Cell Biol. 2021;220:e202101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8404466</ArticleId><ArticleId IdType="pubmed">34427634</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidrauski C, McGeachy AM, Ingolia NT, Walter P. The small molecule ISRIB reverses the effects of eIF2&#x3b1; phosphorylation on translation and stress granule assembly. Elife. 2015;4:e05033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4341466</ArticleId><ArticleId IdType="pubmed">25719440</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker SJ, Meyerowitz J, James JL, Liddell JR, Nonaka T, Hasegawa M, et al. Inhibition of TDP-43 accumulation by bis(thiosemicarbazonato)-copper complexes. PLoS ONE. 2012;7:e42277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3411774</ArticleId><ArticleId IdType="pubmed">22879928</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi S, Thammisetty SS, Codron P, Rahimian R, Plourde KV, Soucy G, et al. Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology. J Clin Investig. 2019;129:1581&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6436898</ArticleId><ArticleId IdType="pubmed">30667370</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaki Y, Shodai A, Morimura T, Hikiami R, Minamiyama S, Ayaki T, et al. Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-specific intrabody with dual proteolytic signals. Sci Rep-uk. 2018;8:6030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5902603</ArticleId><ArticleId IdType="pubmed">29662239</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Raju G, Sivalingam V, Girdhar A, Verma M, Vats A, et al. An acridine derivative, [4,5-bis{(N-carboxy methyl imidazolium)methyl}acridine] dibromide, shows anti-TDP-43 aggregation effect in ALS disease models. Sci Rep-uk. 2016;6:39490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5175139</ArticleId><ArticleId IdType="pubmed">28000730</ArticleId></ArticleIdList></Reference><Reference><Citation>Mompe&#xe1;n M, de Mingo DR, Herv&#xe1;s R, del Carmen Fern&#xe1;ndez-Ram&#xed;rez M, Carri&#xf3;n-V&#xe1;zquez M, Laurents DV. Molecular mechanism of the inhibition of TDP-43 amyloidogenesis by QBP1. Arch Biochem Biophys. 2019;675:108113.</Citation><ArticleIdList><ArticleId IdType="pubmed">31568752</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Fare CM, Shorter J. Therapeutic dissolution of aberrant phases by nuclear-import receptors. Trends Cell Biol. 2019;29:308&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6750949</ArticleId><ArticleId IdType="pubmed">30660504</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Kim HJ, Wang H, Monaghan J, Freyermuth F, Sung JC, et al. Nuclear-import receptors reverse aberrant phase transitions of RNA-binding proteins with prion-like domains. Cell. 2018;173:677&#x2013;692.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911940</ArticleId><ArticleId IdType="pubmed">29677512</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshizawa T, Ali R, Jiou J, Fung HYJ, Burke KA, Kim SJ, et al. Nuclear import receptor inhibits phase separation of FUS through binding to multiple sites. Cell. 2018;173:693&#x2013;705.e22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234985</ArticleId><ArticleId IdType="pubmed">29677513</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq A, Lin J, Jackrel ME, Hesketh CD, Carman PJ, Mack KL, et al. Mining disaggregase sequence space to safely counter TDP-43, FUS, and &#x3b1;-synuclein proteotoxicity. Cell Rep. 2019;28:2080&#x2013;2095.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6750954</ArticleId><ArticleId IdType="pubmed">31433984</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau DHW, Hartopp N, Welsh NJ, Mueller S, Glennon EB, M&#xf3;rotz GM, et al. Disruption of ER&#x2212;mitochondria signalling in fronto-temporal dementia and related amyotrophic lateral sclerosis. Cell Death Dis. 2018;9:327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5832427</ArticleId><ArticleId IdType="pubmed">29491392</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Wang L, Gao C, Arakawa H, Perry G, Wang X. TDP-43 inhibitory peptide alleviates neurodegeneration and memory loss in an APP transgenic mouse model for Alzheimer&#x2019;s disease. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2020;1866:165580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6861700</ArticleId><ArticleId IdType="pubmed">31678156</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G, Gautier O, Tassoni-Tsuchida E, Ma XR, Gitler AD. ALS genetics: gains, losses, and implications for future therapies. Neuron. 2020;108:822&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Butti Z, Patten SA. RNA Dysregulation in amyotrophic lateral sclerosis. Front Genet. 2019;9:712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6349704</ArticleId><ArticleId IdType="pubmed">30723494</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaepfel BL, Rothstein JD. RNA is a double-edged sword in ALS pathogenesis. Front Cell Neurosci. 2021;15:708181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8326408</ArticleId><ArticleId IdType="pubmed">34349625</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussbacher JK, Tabet R, Yeo GW, Lagier-Tourenne C. Disruption of RNA metabolism in neurological diseases and emerging therapeutic interventions. Neuron. 2019;102:294&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6545120</ArticleId><ArticleId IdType="pubmed">30998900</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, Ju S, Arjun A, Batarse A, Archbold HC, Peisach D, et al. Amelioration of toxicity in neuronal models of amyotrophic lateral sclerosis by hUPF1. Proc Natl Acad Sci. 2015;112:7821&#x2013;7826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4485101</ArticleId><ArticleId IdType="pubmed">26056265</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson KL, Dayton RD, Orchard EA, Ju S, Ringe D, Petsko GA, et al. Preservation of forelimb function by UPF1 gene therapy in a rat model of TDP-43-induced motor paralysis. Gene Ther. 2015;22:20&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4924570</ArticleId><ArticleId IdType="pubmed">25354681</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723&#x2013;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Echevarr&#xed;a L, Aupy P, Goyenvalle A. Exon-skipping advances for Duchenne muscular dystrophy. Hum Mol Genet. 2018;27:R163&#x2013;R172.</Citation><ArticleIdList><ArticleId IdType="pubmed">29771317</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampmann M. A CRISPR approach to neurodegenerative diseases. Trends Mol Med. 2017;23:483&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5604856</ArticleId><ArticleId IdType="pubmed">28478951</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampmann M. CRISPRi and CRISPRa screens in mammalian cells for precision biology and medicine. ACS Chem Biol. 2018;13:406&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886776</ArticleId><ArticleId IdType="pubmed">29035510</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>